Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Jersey
Clinical trial register · United States · industry-sponsored

Clinical Trials in New Jersey, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC34 AstraZeneca31 Novartis Pharmaceuticals24 Bristol-Myers Squibb22 Pfizer21
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in New Jersey

782 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
NCT06708455Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
DrugRAPA
Rapa Therapeutics LLC
Phase 2
65
New Jersey
2027-03-01
Not yet open
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
DrugSafusidenib
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, New Jersey, New York, Ohio
2027-03
Not yet open
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07848295Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsCabozantinib·Opdivo·Nivolumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Connecticut, New Jersey, New York, Ohio, Texas, Washington
2026-12-31
Not yet open
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NCT07806773NSCLC, Non Small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 2
80
California, New Jersey
2026-11
Not yet open
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Malignant Neoplam, Advanced Solid Tumors
DrugsMK-2010·Belzutifan·Fluorouracil·Leucovorin
Merck Sharp & Dohme LLC
Phase 2
480
New Jersey, Ohio, Oregon
2026-10-27
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-15
Not yet open
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
DrugsObrixtamig·Pumitamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 1/2
55
Florida, Massachusetts, New Jersey, New York, Tennessee
2026-10-05
Not yet open
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
NCT07743541Uterine Endometrial Cancer
Gilead Sciences
Phase 1/2
100
California, New Jersey, New York, Utah
2026-10
Recruiting
First-in-human Study of UX016 in GNEM
NCT07511556GNE Myopathy
Ultragenyx Pharmaceutical Inc
Phase 1/2
24
California, New Jersey
2026-10
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Recruiting
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
NCT07845071Pain
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
NCT07743151Healthy
Merck Sharp & Dohme LLC
Phase 1
400
Florida, New Jersey, Ohio
2026-09-10
Not yet open
Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder
NCT07780786Overactive Bladder (OAB)
NinaMED Pty Ltd
Phase 3
290
New Jersey
2026-09-10
Recruiting
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
NCT07543055Prostate Cancer
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
NCT07192471T-cell NHL (PTCL or CTCL)
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Not yet open
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
Recruiting
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
NCT07759154Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Not yet open
Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage .
NCT07661004Photodamage of the Face, Anti Aging
L'Oreal
Not applicable
130
New Jersey
2026-09-01
Not yet open
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
NCT07214974Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
Noah Tech, Corp.
Phase EARLY_PHASE1
600
New Jersey
2026-09-01
Recruiting
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
NCT07140939Subcutaneous Fat
DrugCBL-514
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Illinois, Louisiana, Maryland, Nebraska, New Jersey, New York
2026-09-01
Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
NCT07588672Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Polyrizon Ltd.
Not applicable
120
Illinois, Missouri, New Jersey, Texas
2026-09-01
Not yet open
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
NCT07832136Thyroid Eye Disease
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-09
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Not yet open
Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07140497Hearing Disability, Anxiety, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Not yet open
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07195292Hearing Disability, Depression, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants
NCT07848659Sleep Deprivation
Harmony Biosciences Management, Inc.
Phase 1
12
New Jersey
2026-08-28
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555Diabetic Retinopathy, Macular Edema
DrugsTiespectus·Eylea·Aflibercept
Merck Sharp & Dohme LLC
Phase 3
960
California, Colorado, Florida, Maryland, New Jersey, New York, North Carolina, South Carolina
2026-08-27
Recruiting
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
NCT07750158Colorectal Cancer
Drugs) Berahyaluronidase alfa·Zanzalintinib·Pembrolizumab
Exelixis
Phase 3
600
Iowa, Nebraska, New Jersey
2026-08-25
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
NCT07765446Chemotherapy-induced Peripheral Neuropathy
Sironax USA, Inc.
Phase 2
18
Florida, Maryland, New Jersey
2026-08-21
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
Recruiting
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07767903Generalized Anxiety Disorder
DrugUlotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
384
California, Florida, New Jersey, New York, Washington
2026-08-06
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
NCT07778836Friedreich Ataxia, Friedreich's Ataxia
DrugNomlabofusp
Larimar Therapeutics, Inc.
Phase 3
150
Illinois, New Jersey, Texas
2026-08-05
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
Arkansas, California, Florida, New Jersey, Virginia
2026-08-04
Recruiting
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493Schizophrenia
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Not yet open
TeleABA for Hospitalized Adolescents and Young Adults With Autism Spectrum Disorder
NCT07701915Autism Spectrum Disorder (ASD)
Caring Technologies, Inc.
Not applicable
120
New Jersey
2026-08-01
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
California, Florida, Michigan, New Jersey, Texas
2026-08
Recruiting
Study of EVO756 in Adults With Migraine
NCT07616128Migraine
Evommune, Inc.
Phase 2
330
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New Jersey
2026-07-29
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213Dementia, Alzheimer's Type, Alzheimer's Disease
Sanofi
Phase 2
160
California, Florida, Massachusetts, New Jersey, Oregon, Pennsylvania, Texas
2026-07-28
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795Colorectal Cancer
DrugsVS-7375·Panitumumab·MFOLFOX6·Cetuximab
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, Tennessee
2026-07-28
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596Relapsed or Refractory Multiple Myeloma
DrugsAldesleukin·Daratumumab
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
By invitation
OsseoFit Stemless Shoulder System (Anatomic)
NCT07421245Shoulder Injuries, Shoulder Pain, Shoulder Fractures, Shoulder Arthritis
Zimmer Biomet
Observational
136
New Jersey, New York
2026-07-23
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782Non-Small Cell Lung Cancer
DrugVS-7375
Verastem, Inc.
Phase 2
105
California, Florida, Georgia, New Jersey, New York, Texas, Virginia
2026-07-22
Recruiting
Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA
NCT07275151Atrial Fibrillation
CathVision ApS
Observational
40
Michigan, New Jersey
2026-07-22
Recruiting
Study of GS-0415 and How It Works in People With HIV
NCT07719491HIV -1 Infection
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974Malignant Neoplasm
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Iowa, Massachusetts, Michigan, New Jersey, New York, North Dakota
2026-07-06
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
California, Illinois, New Jersey, New York
2026-07-02
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Recruiting
A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07677254Prostatic Neoplasms, Castration-Resistant
Novartis Pharmaceuticals
Observational
17,111
New Jersey
2026-06-30
Recruiting
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
NCT07677267Prostatic Neoplasms, Castration-Resistant
Novartis Pharmaceuticals
Observational
1,067
New Jersey
2026-06-30
Not yet open
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
NCT07618715Healthy Male and Female Subjects
DrugsY-4·Riluzole·Pregabalin
Neurodawn Pharmaceutical Co., Ltd.
Phase 1
11
New Jersey
2026-06-30
Recruiting
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787Renal Transplant Failure and Rejection
DrugsSiplizumab·Rabbit anti-thymocyte globulin·Thymoglobulin
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Michigan, New Jersey, Texas, Washington
2026-06-29
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas
2026-06-23
Recruiting
The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia
NCT07841509Migraine, Fibromyalgia, Conditioned Pain Modulation
Theranica
Not applicable
120
New Jersey
2026-06-23
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Follicular Lymphoma
DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, North Carolina, Tennessee
2026-06-22
By invitation
An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07670702Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
NCT07644052Cannabis Withdrawal
DrugNabilone
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
180
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey
2026-06-16
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
By invitation
Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System
NCT07758907Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use
Intelligent Bio Solutions Inc.
Not applicable
95
New Jersey
2026-06-15
Recruiting
A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
NCT07635316Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals
Observational
4,023
New Jersey
2026-06-12
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Not yet open
Cell Free Preimplantation Genetic Testing
NCT04628507Infertility, Female, Infertility, Male
Genomic Prediction Inc.
Observational
200
New Jersey
2026-06-11
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide
NCT07672119Prostate Cancer
Bayer
Observational
3,000
New Jersey
2026-06-04
Recruiting
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
NCT07732907Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
DrugOzanimod
Bristol-Myers Squibb
Observational
15
New Jersey
2026-06-04
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Method Comparison of Intelligent Fingerprinting Drug Screening System
NCT07650136Drug Abuse Illicit
Intelligent Bio Solutions Inc.
Observational
144
New Jersey
2026-06-02
Recruiting
Study of GS-2426 in Participants With Advanced Solid Tumors
NCT07601243Advanced Solid Tumors
Gilead Sciences
Phase 1
174
Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
NCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.
Phase 2
15
Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas
2026-06-02
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Pembrolizumab
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06
Recruiting
Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.
NCT07270380Osteomyelitis
Biocomposites Ltd
Not applicable
139
California, Indiana, Maryland, New Jersey
2026-06
Not yet open
GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial
NCT07551531Kidney Transplant
Insight Molecular Diagnostics
Observational
5,000
New Jersey
2026-06
Not yet open
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-06
Recruiting
Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation
NCT07331285Obstructive Sleep Apnea
Nyxoah Inc.
Observational
229
Florida, New Jersey
2026-06
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, Maryland, New Jersey, New York, Ohio
2026-05-27
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsZoldonrasib·Leucovorin·Irinotecan·Adrucil
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
New Jersey, New York, Tennessee
2026-05-21
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Maryland, Nebraska, New Jersey, Ohio
2026-05-18
Recruiting
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
NCT07529717Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
42
Florida, New Jersey, Rhode Island
2026-05-18
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
NCT07600736KCNT1-Related Epilepsy
DrugABS-1230
Actio Biosciences, Inc.
Phase 2
55
New Jersey
2026-05-18
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York
2026-05-14
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Active, closed
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease
NCT07723950Alzheimer's Disease
Eisai Inc.
Observational
600
New Jersey
2026-05-11
Active, closed
Relative Bioavailability Study of HNC364 Injectable Suspension
NCT06798519Parkinson's Disease (PD)
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 1
30
New Jersey
2026-05-08
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York
2026-05-04
Recruiting
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
NCT07607678Advanced Solid Cancer, Metastatic Solid Cancer
DrugEzabenlimab
Boehringer Ingelheim
Phase 1
60
Connecticut, New Jersey, New York, Tennessee
2026-05-01
Not yet open
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
NCT07588984Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
DrugsTirzepatide·Semaglutide
Noom Inc.
Observational
2,310
New Jersey
2026-04-30
Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052Non-small Cell Lung Cancer (NSCLC)
DrugsSetidegrasib·Docetaxel
Astellas Pharma Global Development, Inc.
Phase 3
356
California, New Jersey, Virginia
2026-04-28
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
New Jersey, New York, Ohio, Washington
2026-04-28
Recruiting
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428Negative Symptoms of Schizophrenia
DrugsAripiprazole·Risperidone·Olanzapine
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667Chronic Lymphocytic Leukemia, B-cell Malignancies
DrugsEmavusertib·Zanubrutinib
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio
2026-04-23
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
Connecticut, Florida, Iowa, Michigan, Mississippi, New Jersey, South Carolina, Texas
2026-04-17
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, New Jersey, Ohio, Oregon, Pennsylvania, South Dakota
2026-04-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
NCT07286032Patients With Chemotherapy-Induced Thrombocytopenia
DrugHetrombopag Olamine
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
150
California, Florida, Illinois, Iowa, Mississippi, Nebraska, New Jersey, New York
2026-04-16
By invitation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
NCT07444489Antibody-mediated Rejection, Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
Active, closed
P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation
NCT07471308Atrial Fibrillation (AF), Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, Atrial Fibrillation (Paroxysmal), Pulmonary Vein Isolation
CathVision ApS
Observational
300
New Jersey
2026-04-13
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
NCT07779460Multiple Sclerosis
Novartis Pharmaceuticals
Observational
7,466
New Jersey
2026-04-08
Recruiting
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
NCT07500506Lyme Disease
DrugVLA15
Pfizer
Phase 3
1,712
Maine, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia
2026-04-08
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112Refractory Melanoma
DrugDOC1021
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
EpiBiologics
Phase 1
110
California, New Jersey, New York, Tennessee, Texas
2026-03-31
Recruiting
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
NCT07736937Ovarian Cancer
DrugsTUB-040·Carbo
Gilead Sciences
Phase 1/2
72
California, New Jersey, New York
2026-03-30
Recruiting
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439Nausea and Vomiting, Obesity
DrugTradipitant
Vanda Pharmaceuticals
Phase 3
280
California, Florida, New Jersey, New York, Texas, Virginia
2026-03-27
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Michigan, New Jersey
2026-03-25
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
DrugFulvestrant
IDEAYA Biosciences
Phase 1
160
Florida, New Jersey, New York, Texas, Utah, Virginia
2026-03-17
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
NCT07285070Non-infectious Anterior Uveitis
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
DrugsEnfortumab Vedotin·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, Illinois, Indiana, Michigan, New Jersey, New York, Pennsylvania, South Carolina
2026-03-12
Active, closed
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
NCT07562087Lyme Disease
Tarsus Pharmaceuticals, Inc.
Phase 2
722
Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Active, closed
A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy
NCT07844070Multiple Sclerosis
Novartis Pharmaceuticals
Observational
2,607
New Jersey
2026-03-06
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838Generalized Myasthenia Gravis, gMG
DrugsPrednisone/Prednisolone·Ravulizumab
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
DrugIDE397
IDEAYA Biosciences
Phase 1
260
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602Atopic Dermatitis (AD), Eczema
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Recruiting
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
NCT07465965Overweight, Obesity
DrugSemaglutide
Shanghai World Leader Pharmaceutical Co., Ltd.
Phase 1
60
New Jersey
2026-03-02
Recruiting
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
NCT07471048Psoriasis
Sirt3 LLC
Not applicable
100
New Jersey
2026-03-01
Not yet open
Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates
NCT07060911RDS of Prematurity, Preterm Birth, Lung Diseases
Neola Medical Inc
Not applicable
22
California, New Jersey
2026-03
Recruiting
COPD Exacerbation Follow Up
NCT07118306COPD (Chronic Obstructive Pulmonary Disease)
Viz.ai, Inc.
Observational
485
Illinois, New Jersey, Pennsylvania, Virginia, Wisconsin
2026-02-27
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998Breast Cancer
DrugsInavolisib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
California, Florida, Missouri, New Jersey
2026-02-18
Recruiting
A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
NCT06894329Pancreatic Cystic Lesions
Amplified Sciences Inc
Observational
50
Indiana, Massachusetts, New Jersey
2026-02-17
Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995Locally Advanced or Metastatic Malignant Solid Tumors
DrugsEnfortumab Vedotin·Keytruda·Carboplatin·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 1/2
428
New Jersey, New York, Tennessee, Virginia
2026-02-05
Recruiting
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
NCT07446582Age-Related (Dry) Macular Degeneration
AI-Spectral
Observational
1,000
New Jersey
2026-02-01
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177Non-small Cell Lung Cancer (NSCLC)
DrugRina-S
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSmile® Aligners.
NCT07290790Malocclusion
Dentsply Sirona Implants and Consumables
Not applicable
90
California, New Jersey, North Carolina, Texas
2026-01-29
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Active, closed
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
NCT07505004Focal Epilepsy
Praxis Precision Medicines
Phase 3
300
Florida, New Jersey, New York, North Carolina, Texas
2026-01-29
Active, closed
Effects of a Topical Serum Solution on Hair Characteristics
NCT07785869Hair Characteristics
DrugMinoxidil
Pacagen, Inc.
Not applicable
190
New Jersey, Virginia
2026-01-26
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Recruiting
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
NCT07247188Sickle Cell Disease
DrugsCapvaxive·Prevnar 20
Sanofi
Phase 3
100
Georgia, Nebraska, New Jersey, Texas
2026-01-20
Recruiting
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 4
60
Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas
2026-01-20
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Eikon Therapeutics
Phase 1/2
160
California, Florida, New Jersey, New York, Texas
2026-01-20
Recruiting
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
NCT07408219Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
350
New Jersey
2026-01-17
Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT07049055Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsNab-paclitaxel·Gemcitabine
Engeneic Pty Limited
Phase 1/2
144
California, New Jersey, New York, Ohio
2026-01-12
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
NCT07358078Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Kansas, Massachusetts, Missouri, New Jersey, North Carolina
2026-01-09
Active, closed
Nerivio Efficacy Under High-Frequency Use
NCT07336056Migraine
Theranica
Phase 4
2,000
New Jersey
2026-01-08
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
NCT07158775Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
DrugBS01
Bionic Sight LLC
Phase 1/2
40
New Jersey
2026-01-08
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2026-01-07
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
By invitation
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
NCT07713901Medullary Thyroid Carcinoma
Novo Nordisk A/S
Observational
93,600,000
New Jersey
2025-12-31
Recruiting
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320Bipolar I Disorder, Mania
DrugNBI-1117568
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
85
California, Nevada, New Jersey, Texas
2025-12-18
Recruiting
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247Solid Tumors, Adult
Hutchmed
Phase 1/2
147
Colorado, Florida, New Jersey, New York, Ohio, Washington
2025-12-16
Recruiting
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
NCT07247110Malignant Neoplasm
DrugsCetuximab·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
250
New Jersey, Texas, Virginia
2025-12-16
Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928Advanced Or Metastatic Merkel Cell Carcinoma
DrugsIFx-Hu2.0·Keytruda·Pembrolizumab
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591Glioblastoma
DrugTemozolomide
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Florida, Georgia, Maryland, New Hampshire, New Jersey, New York
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
California, New Jersey, South Carolina, Texas
2025-12-09
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
80
California, Florida, New Jersey, New York, Oregon, Tennessee
2025-12-09
Recruiting
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
NCT07786077Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Observational
100
New Jersey
2025-12-08
Recruiting
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993Breast Cancer
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 1
60
Florida, Maryland, Minnesota, New Jersey
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
Study to Evaluate CAY001 in Healthy Volunteers
NCT06845839Healthy
Cayuga Biotech, Inc.
Phase 1
24
New Jersey
2025-12-02
Active, closed
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
NCT07236606MPS II, Hunter Syndrome (MPS II)
REGENXBIO Inc.
Phase 3
2
New Jersey
2025-11-25
Active, closed
A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
NCT07226882Lyme Borreliosis
DrugVLA15
Pfizer
Phase 3
207
New Jersey, New York, Pennsylvania
2025-11-19
Recruiting
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
NCT07209098Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Impulse Dynamics
Observational
4,200
New Jersey
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Active, closed
Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)
NCT07849660Carcinoma, Hepatocellular
DrugLenvatinib
Eisai Inc.
Observational
170
New Jersey
2025-11-17
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Active, closed
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577Atopic Dermatitis
DrugGIA632
Novartis Pharmaceuticals
Phase 2
34
California, Maryland, New Jersey
2025-11-10
Recruiting
Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers
NCT07396376Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Eluciderm Inc
Phase 1/2
15
Illinois, New Jersey, Texas
2025-11-10
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225Non-muscle Invasive Bladder Cancer
DrugSasanlimab
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT07219511Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Active, closed
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07214961Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc.
Phase 1
80
Michigan, Nebraska, New Jersey
2025-11-03
By invitation
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
DrugsAglatimagene besadenovec·Valacyclovir
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
Recruiting
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT06992258Colorectal Cancer
DrugsLonsurf·Fruquintinib
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
The HEARTFELT Study
NCT06222099Heart Failure, Chronic Heart Failure
Heartfelt Technologies
Not applicable
1,500
Arkansas, New Jersey, Pennsylvania
2025-10-23
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Active, closed
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
NCT07008378Multiple Sclerosis
DrugsFludarabine·Cyclophosphamide
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
Recruiting
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
NCT07210021Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
AccurKardia, Inc.
Observational
50
New Jersey
2025-10-14
Recruiting
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
NCT06655883Insomnia
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, Connecticut, Florida, Georgia, Indiana, Maine, New Jersey, New York
2025-10-08
Recruiting
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
NCT07219030Healthy Volunteer
DrugEmraclidine
AbbVie
Phase 1
52
California, Florida, Illinois, New Jersey
2025-10-08
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488Multiple Myeloma
DrugsMezigdomide·Elranatamab·Dexamethasone
Celgene
Phase 1/2
62
Alabama, Connecticut, New Jersey, Texas
2025-10-07
Recruiting
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
NCT07142304Chemotherapy Induced Peripheral Neuropathy (CIPN)
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Not yet open
Evaluating the Bambini Teens Exoskeleton for Pediatric Cerebral Palsy
NCT07146932Cerebral Palsy (CP)
COSMO ROBOTICS CO., Ltd
Not applicable
20
New Jersey
2025-10
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, New Jersey, New York, Texas, Virginia
2025-09-24
Recruiting
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094Schizophrenia
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT06052254Agitation
Teikoku Pharma USA, Inc.
Phase 2
150
California, Florida, Massachusetts, New Jersey
2025-09-16
Recruiting
Phagenyx® Registry Study
NCT06866418Dysphagia
Phagenesis Ltd.
Observational
600
Arizona, New Jersey, Texas
2025-09-15
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
DrugsRestoret·Aflibercept
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
By invitation
An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product
NCT07136766Hyperpigmentation
Good Molecules, LLC
Phase 3
40
New Jersey
2025-09-10
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Active, closed
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
NCT07092254Triple Negative Breast Cancer
Daiichi Sankyo
Observational
760
New Jersey
2025-09-01
Recruiting
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.
Phase 2
150
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2025-08-27
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103Solid Tumors
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Psychosis Associated With Alzheimer's Disease
DrugML-007C-MA
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Louisiana, Nevada, New Jersey
2025-08-15
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06896916Multiple Myeloma
DrugsEtentamig·Iberdomide
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918Schizophrenia
DrugEmraclidine
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
DrugBL-M05D1
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Active, closed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
NCT06978244Ocular Pain
Bausch & Lomb Incorporated
Phase 1
24
New Jersey
2025-07-29
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
DrugRisankizumab
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Recruiting
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
NCT07030712Metastatic Neoplasm
Merck Sharp & Dohme LLC
Phase 1
67
Illinois, New Jersey, Texas
2025-07-23
Recruiting
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
NCT07038785Breast Cancer
SpotitEarly
Observational
1,204
New Jersey, Pennsylvania
2025-07-22
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey
2025-07-21
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
Kelonia Therapeutics, Inc.
Phase 1
70
California, Florida, Georgia, Massachusetts, New Jersey, Oregon
2025-07-16
Recruiting
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494Early Alzheimer's Disease
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Not yet open
A Clinical Study on the Effects of a Dietary Supplement on Stress, Anxiety, Mood and Sleep in a Pediatric Population
NCT07076537Healthy
Olly, PBC
Not applicable
80
New Jersey
2025-07-15
Active, closed
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471Developmental and Epileptic Encephalopathy 1
DrugRelutrigine
Praxis Precision Medicines
Phase 3
160
California, Florida, Maryland, Minnesota, New Jersey, Pennsylvania
2025-07-09
Recruiting
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
NCT06714864Catheter-Related Infections
Drug(taurolidine and heparin) catheter lock
CorMedix Therapeutics
Phase 4
36
Alabama, Arizona, California, Delaware, New Jersey, Texas
2025-07-08
Recruiting
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733Neurotrophic Keratitis
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
Transcranial Direct Current Stimulation for Depression
NCT07042217Unipolar Depression
Soterix Medical
Not applicable
25
New Jersey
2025-07-01
Recruiting
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
NCT07082829Excessive Daytime Sleepiness
Centessa Pharmaceuticals (UK) Limited
Phase 1
208
Nebraska, New Jersey, New York
2025-06-30
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
NCT07015905Venous Thromboembolism (VTE)
DrugsCenvacibart·Enoxaparin·Apixaban
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Recruiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926Nausea, Vomiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Recruiting
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
NCT07012291Coagulation
Perosphere Technologies Inc.
Observational
150
Connecticut, Maryland, New Jersey, New York
2025-06-20
Active, closed
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT06912633Retinitis Pigmentosa
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
NCT06283979Pressure Ulcer, Stage IV, Osteomyelitis
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
BioHealx® Anal Fistula Device Post Market Surveillance Study
NCT07021742Fistula-in-ano
Signum Surgical USA Inc.
Observational
50
Florida, New Jersey, New York, Pennsylvania
2025-06-14
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614Nonmuscle-invasive Bladder Cancer
DrugT3011
ImmVira Pharma Co. Ltd
Phase 2
160
Arizona, California, Florida, New Jersey, Ohio, Pennsylvania, South Carolina
2025-06-09
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
NCT06872905Aortoiliac Occlusive Disease
W.L.Gore & Associates
Observational
158
California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2025-05-30
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Arkansas, California, New Jersey, Virginia, Washington
2025-05-29
Recruiting
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
NCT07821658Alzheimer's Disease
Eisai Inc.
Observational
6,700
New Jersey
2025-05-23
Recruiting
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
DrugsBNT324·Pumitamig
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Active, closed
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
DrugsSTK-009·SYNCAR-001
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
NCT06394869Hematuria - Cause Not Known
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
DrugAtezolizumab
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
Pivotal Study for the Cardiac Performance System (CPS)
NCT06870591Cardiovascular Diseases
Sensydia Corporation
Observational
1,000
Alabama, Illinois, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee
2025-04-22
Active, closed
A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery
NCT06664788Hemostasis, Hemostatic Techniques
Ethicon, Inc.
Not applicable
108
California, Missouri, New Jersey, New York, Texas, Utah
2025-04-16
By invitation
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Recruiting
Home Reported Outcomes in C3G Study
NCT07029542C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
100
New Jersey
2025-04-07
Active, closed
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
NCT06973720Obesity, Overweight or Obesity
DrugBerobenatide
Pfizer
Phase 2
268
Florida, Georgia, New Jersey
2025-04-07
Not yet open
Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters
NCT06906055Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization
Summa Therapeutics, LLC
Not applicable
24
Delaware, New Jersey
2025-04-03
Active, closed
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
NCT06864169Gastrointestinal Cancer
DrugR-DXd
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
Self-balancing Personal Exoskeleton for SCI (Site 2)
NCT06814015Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Wandercraft
Not applicable
24
New Jersey
2025-03-31
Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
Context Therapeutics Inc.
Phase 1
70
Colorado, Illinois, Michigan, New Jersey, Pennsylvania, Tennessee, Texas
2025-03-31
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Florida, Michigan, Nevada, New Jersey, New York
2025-03-28
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Active, closed
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
NCT06869187Bipolar Disorder Depression
DrugABX-002
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
DrugsGEMNabP·MFOLFIRINOX·Cetuximab
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Active, closed
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427Aortic Stenosis Symptomatic
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
NCT06764771Advanced Malignant Tumors
DrugsAdagrasib·Erbitux·Opdivo·Cetuximab
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Alabama, Florida, New Jersey, Texas, Virginia
2025-03-25
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305Glioblastoma (GBM)
DrugsDOC1021·Temodar·Temozolomide
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Active, closed
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
NCT06495424Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
DrugCapsaicin
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
DrugsTobevibart·Elebsiran
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756Acute Myeloid Leukaemia (AML)
DrugCytarabine
Moleculin Biotech, Inc.
Phase 2/3
312
Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island
2025-03-12
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
DrugsCobolimab·Dostarlimab
GlaxoSmithKline
Phase 1/2
83
California, Iowa, New Jersey, Ohio, Rhode Island, Wisconsin
2025-03-06
Active, closed
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621Alzheimer&#39;s Disease (AD)
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
DrugALN-4324
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Active, closed
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212Schizophrenia
DrugUlotaront
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394Breast Neoplasms, Breast Cancer
DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib
Merck Sharp & Dohme LLC
Phase 1/2
81
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
NCT06810960Alzheimer's Disease
Eisai Korea Inc.
Observational
3,000
New Jersey
2025-02-24
By invitation
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
NCT06878976Binge-Eating Disorder
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
236
California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey
2025-02-20
Recruiting
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197Advanced Solid Tumors
DrugsNivolumab and rHuPH20·Opdualag·Bevacizumab
Bristol-Myers Squibb
Phase 1/2
413
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism
NCT07590973Autism, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Neurodevelopmental Conditions
Blinklab Limited
Observational
1,000
New Jersey
2025-02-15
Active, closed
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
NCT06730750Advanced Solid Tumors
DrugBevacizumab
Bristol-Myers Squibb
Phase 1/2
360
California, Michigan, New Jersey, Pennsylvania
2025-02-12
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
DrugsPumitamig·Iza-bren·Osimertinib·Opdivo
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Recruiting
Non-Invasive Preeclampsia Screening and Biobank
NCT06643741Preeclampsia (PE)
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
By invitation
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
NCT06701201Cancer
DrugSynKIR-310
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Active, closed
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463Acute Myeloid Leukemia
DrugsTagraxofusp·Venclexta·Azacitidine·Venetoclax
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807Phenylketonurias
NGGT INC.
Phase 1/2
12
California, Minnesota, New Jersey, Pennsylvania, Texas
2025-01-10
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Fortvita Biologics (USA)Inc.
Phase 1
250
California, New Jersey, Texas, Virginia
2025-01-10
Recruiting
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
NCT06809179Social Anxiety Disorder
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Recruiting
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
NCT07314346Healthy Volunteer Study
DrugsBEM/RZR·Buprenorphine/Naloxone·Methadone
Atea Pharmaceuticals, Inc.
Phase 1
32
Florida, Kansas, New Jersey
2025-01-07
Active, closed
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
NCT06765681Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
Bayer
Observational
10,000
New Jersey
2025-01-06
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
Zirconia Implants: Practice-based Evidence
NCT06314425Dental Implants, Ceramic Implant
Swiss Dental Solutions
Not applicable
50
New Jersey
2025-01-03
Active, closed
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
NCT06744673Sleep Initiation and Maintenance Disorders, Pregnancy
Eisai Inc.
Observational
861
New Jersey
2025-01-03
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Recruiting
The Lily Device Trial
NCT06786078Chemotherapy Induced Alopecia
Luminate Medical, Inc.
Not applicable
85
New Jersey, New York, Pennsylvania
2024-12-20
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Active, closed
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
NCT06741228Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey
2024-12-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
DrugsAutogene cevumeran·Opdivo·Nivolumab
Hoffmann-La Roche
Phase 2
62
New Jersey, New York, Washington
2024-12-09
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
DrugsJNJ-90301900·Durvalumab
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Active, closed
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396Metastatic Breast Cancer
DrugsBelzutifan·Exemestane·Everolimus·Fulvestrant
Merck Sharp & Dohme LLC
Phase 2
120
Arizona, California, Georgia, Louisiana, Nevada, New Jersey, Texas, Wisconsin
2024-11-27
Recruiting
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
Peerbridge Health, Inc
Observational
2,000
California, Michigan, New Jersey, New York, North Carolina, Texas
2024-11-21
Recruiting
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
NCT06589440Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
DrugsBalstilimab·Botensilimab
Stingray Therapeutics
Phase 2
70
New Jersey, Texas, Washington
2024-11-20
Recruiting
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
NCT06702449Urinary Tract Infections
GlaxoSmithKline
Phase 1/2
448
Kansas, New Jersey, New York, Texas, Washington
2024-11-19
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192Breast Reconstruction
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
DrugsNKX019·Fludarabine·Cyclophosphamide
Nkarta, Inc.
Phase 1/2
240
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-11-04
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugSynKIR-310
Verismo Therapeutics
Phase 1
36
Colorado, Georgia, Kansas, New Jersey, Pennsylvania
2024-11-01
Recruiting
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
NCT06496256Prostate Cancer
Palette Life Sciences, Inc.
Not applicable
84
Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania
2024-10-31
Recruiting
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
NCT06630806Plasma Cell Myeloma Refractory
Sanofi
Phase 1
87
Arizona, Florida, Minnesota, New Jersey, Pennsylvania
2024-10-30
Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768Alzheimer Disease, Healthy
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567Agitation Associated With Alzheimer's Dementia
DrugITI-1284
Intra-Cellular Therapies, Inc.
Phase 2
320
California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas
2024-10-22
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
New Jersey, Texas, Virginia, Wisconsin
2024-10-18
Active, closed
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
NCT06581575Herpes Zoster (HZ), Infectious Diseases, Shingles
DrugShingrix
Immorna Biotherapeutics, Inc.
Phase 2
467
Arizona, California, Illinois, Nebraska, New Jersey, South Carolina, Texas
2024-10-16
Active, closed
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
DrugCapecitabine
Processa Pharmaceuticals
Phase 2
90
Arizona, California, Florida, Indiana, Maryland, New Jersey, New York, Ohio
2024-10-02
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
Phase III Presbyopia Correction Using the VIS Opti-K™ System
NCT06487897Presbyopia
VIS, Inc.
Phase 3
75
Florida, Massachusetts, New Jersey, New York
2024-09-30
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Recruiting
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
DrugsOlvi-Vec·Olvimulogene nanivacirepvec·Docetaxel·Cisplatin
Genelux Corporation
Phase 2
142
Arizona, Florida, Michigan, New Jersey, Ohio, Texas
2024-09-26
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey
2024-09-18
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
DrugAZD5492
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Recruiting
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT06398626Colitis, Ulcerative
DrugEtrasimod
Pfizer
Observational
300
Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York
2024-09-17
Active, closed
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
153
California, Florida, Maryland, Minnesota, New Jersey
2024-09-17
Active, closed
ABA-101 in Participants With Progressive Multiple Sclerosis
NCT06566261Progressive Multiple Sclerosis
Abata Therapeutics
Phase 1
12
Maryland, New Jersey, Ohio
2024-09-11
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
California, New Jersey, Ohio, Texas
2024-09-06
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
California, District of Columbia, Florida, Missouri, New Jersey, New York, Ohio, Pennsylvania
2024-08-21
Active, closed
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733HIV-1-Infection
DrugB/F/TAF
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Recruiting
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
NCT06386874Ischemic Stroke
BrainQ Technologies Ltd.
Not applicable
122
California, District of Columbia, Florida, Georgia, Illinois, Kansas, New Jersey, New York
2024-08-20
Recruiting
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590Alzheimer Disease
Eli Lilly and Company
Phase 1
48
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833Psychotic Disorders, Alzheimer Disease
DrugITI-1284
Intra-Cellular Therapies, Inc.
Phase 2
370
California, Florida, Georgia, New Jersey, North Carolina, Texas, Washington
2024-08-15
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315STEMI - ST Elevation Myocardial Infarction, AMI
TherOx
Observational
1,000
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-08-13
Recruiting
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
NCT06469281Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsMvasi·Cemiplimab·Avastin·Bevacizumab
Regeneron Pharmaceuticals
Phase 1
90
Massachusetts, New Jersey, New York, Pennsylvania, Utah
2024-08-06
Active, closed
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
NCT05831202Intracranial Aneurysm
Galaxy Therapeutics INC
Phase 3
279
Illinois, New Jersey, New York
2024-08-06
Recruiting
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383Generalized Anxiety Disorder
DrugITI-1284
Intra-Cellular Therapies, Inc.
Phase 2
705
California, Florida, Georgia, Michigan, New Jersey, New York, Ohio, Oklahoma
2024-08-05
Active, closed
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
NCT06710470Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Observational
833
New Jersey
2024-08-02
Recruiting
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
NCT06226805Acute Ischemic Stroke
Basking Biosciences, Inc.
Phase 2
228
Arizona, California, Florida, Michigan, Missouri, New Jersey, North Carolina, Ohio
2024-07-31
Recruiting
Vitaccess Real MG Registry
NCT06064461Myasthenia Gravis
Vitaccess Ltd
Observational
600
California, Illinois, Kentucky, New Jersey, South Carolina, Texas
2024-07-31
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
108
California, Kentucky, Maryland, Missouri, Nevada, New Jersey, New York, North Carolina
2024-07-29
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey
2024-07-22
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Florida, Kansas, Missouri, New Jersey, New York, Pennsylvania, Texas
2024-07-19
Active, closed
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
NCT06340451Spasticity, Cerebral or Spinal Condition
Pacira Pharmaceuticals, Inc
Not applicable
132
California, Florida, Georgia, Kansas, Missouri, New Jersey, New York, Pennsylvania
2024-07-11
Recruiting
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037Long Term Follow-up
Arbutus Biopharma Corporation
Observational
50
California, Florida, New Jersey
2024-07-11
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Active, closed
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT06315322Childhood Absence Epilepsy, Juvenile Absence Epilepsy
DrugBrivaracetam
UCB Biopharma SRL
Phase 3
70
Alabama, New Jersey, North Carolina
2024-07-10
Active, closed
Safety and Efficacy of VDPHL01 in Males and Females With AGA
NCT06527365Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 2
70
California, Indiana, New Jersey, Utah
2024-07-08
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
DrugTeprotumumab
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
NCT06188585Acute Gastrointestinal Bleeding
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Recruiting
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
NCT06321575Peripheral Arterial Disease
Nipro Vascular Innovations Americas, Inc
Not applicable
159
Arizona, California, Florida, Georgia, Hawaii, Louisiana, Massachusetts, New Jersey
2024-06-20
Active, closed
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
DrugINZ-701
Inozyme Pharma
Phase 2
22
Minnesota, New Jersey
2024-06-19
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
550
California, Florida, Georgia, Michigan, Missouri, New Jersey, New York, North Dakota
2024-06-11
Recruiting
Home Reported Outcomes in PNH
NCT06411626Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
128
New Jersey
2024-06-11
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
DrugsZanzalintinib·Keytruda·Pembrolizumab
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Active, closed
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
NCT06253923Traumatic Brain Injury
SHINKEI Therapeutics, Inc
Phase 2
45
California, Florida, Maine, Michigan, Missouri, New Jersey, New Mexico, North Carolina
2024-06-01
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Florida, Maryland, New Jersey, Ohio, Wisconsin
2024-05-20
Recruiting
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
NCT06278207Chronic Kidney Disease, Type 2 Diabetes Mellitus
DrugsKerendia·Finerenone
Bayer
Observational
50,000
New Jersey
2024-05-15
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Arizona, California, Florida, Georgia, Kansas, New Jersey, North Carolina, Ohio
2024-04-16
By invitation
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773Chronic Limb-Threatening Ischemia
Aveera Medical, Inc.
Not applicable
120
California, Delaware, Florida, Illinois, Louisiana, Massachusetts, New Hampshire, New Jersey
2024-04-16
Active, closed
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
NCT06125951Dementia Moderate, Dementia, Mild, Alzheimer Disease
Actinogen Medical
Phase 2/3
247
California, Colorado, Florida, Georgia, New Jersey, New York, Ohio, Oregon
2024-04-12
Active, closed
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159Hypertrophic Cardiomyopathy
Edgewise Therapeutics, Inc.
Phase 2
79
California, Georgia, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina
2024-04-11
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Recruiting
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862Advanced Solid Tumor
DrugOlaparib
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Active, closed
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201Multiple Sclerosis, Myasthenia Gravis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT06566092Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma
Iovance Biotherapeutics, Inc.
Phase 1
40
Colorado, Florida, New Jersey, New York
2024-03-28
Active, closed
A Study of ANAVEX3-71 in Adults With Schizophrenia
NCT06245213Schizophrenia
Anavex Life Sciences Corp.
Phase 2
71
New Jersey
2024-03-15
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729Metastatic Prostate Cancer
DrugsAZD0754·AZD2287
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
California, Florida, Missouri, New Jersey, South Dakota, Texas
2024-03-11
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
NCT06190717Diabetes, End Stage Renal Disease
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118Multiple Myeloma
DrugsIberdomide·Elranatamab
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Active, closed
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Breast Cancer
DrugsVepdegestrant·Atirmociclib
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
NCT06088979Thyroid Eye Disease
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nevada, New Jersey
2024-02-19
Active, closed
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096Delayed Graft Function
DrugEmpasiprubart
argenx
Phase 2
103
California, Florida, Illinois, New Jersey, New York, Ohio, Texas
2024-02-17
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin
Janssen Research & Development, LLC
Phase 2
305
Arizona, California, Georgia, Illinois, Missouri, Nevada, New Jersey, New York
2024-02-16
Active, closed
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099Hepatocellular Carcinoma (HCC)
DrugsZirabev·Avastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
Busulfan Sample Collection Study
NCT05711732Subjects Treated With Busulfan
Saladax Biomedical, Inc.
Observational
150
Illinois, New Jersey, Texas
2024-02-08
Active, closed
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820Pompe Disease (Late-onset)
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
NCT06808880Single Gene NIPT
Natera, Inc.
Observational
4,000
Arizona, California, Florida, Mississippi, New Jersey, New York, Texas
2024-01-25
Recruiting
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
NCT06447025Friedreich Ataxia
DrugNomlabofusp
Larimar Therapeutics, Inc.
Phase 2
85
California, Florida, Iowa, Maryland, New Jersey, Ohio, Pennsylvania
2024-01-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Avastin·Keytruda·Bevacizumab
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Recruiting
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069SCLC
DrugsZL-1310·Atezolizumab·Carboplatin
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Active, closed
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
NCT06132113Neuroendocrine Neoplasms
DrugsObrixtamig·Etoposide·Cisplatin·Carboplatin
Boehringer Ingelheim
Phase 1
65
Florida, Georgia, Illinois, New Jersey, Pennsylvania
2024-01-22
Recruiting
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05967416Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc.
Phase 1
24
California, New Jersey, Texas
2024-01-17
Recruiting
Comparing Use of Incentive Spirometry With and Without Reminder
NCT06101030Post Operative
Tidal Medical Technologies
Observational
500
Maryland, Minnesota, New Jersey
2024-01-16
Active, closed
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150Knee Osteoarthritis
Merit Medical Systems, Inc.
Not applicable
264
California, District of Columbia, Georgia, Illinois, Massachusetts, Missouri, New Jersey, New York
2024-01-16
Active, closed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916Diabetic Macular Edema (DME)
DrugsKHK4951·Aflibercept
Kyowa Kirin Co., Ltd.
Phase 2
150
Arizona, California, Colorado, Florida, Maryland, Nevada, New Jersey, New Mexico
2024-01-09
Recruiting
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160Solid Tumors
DrugsGEMNabP·INCB161734·INCA33890·Retifanlimab
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Florida, Massachusetts, New Jersey
2023-12-30
Active, closed
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
NCT05685004Glioblastoma Multiforme of Brain
DrugTemozolomide
TVAX Biomedical
Phase 2/3
120
Arizona, California, Florida, Georgia, Kansas, New Jersey, Oregon
2023-12-27
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511Multiple Myeloma
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
DrugAZD5851
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
DrugsAcalabrutinib·Venetoclax·Rituximab
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
181
California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia
2023-12-13
Recruiting
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074Advanced Solid Malignancies
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Active, closed
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786Carcinoma, Non-small-Cell Lung
DrugsJNJ-86974680·Cetrelimab
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Recruiting
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963Moderate Alzheimer Disease
DrugSNK01
NKGen Biotech, Inc.
Phase 1/2
36
California, Florida, New Jersey, New York
2023-11-21
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, Ltd
Phase 1
9
New Jersey, New York
2023-11-09
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
DrugBMS-986435
Bristol-Myers Squibb
Phase 2
227
Alabama, Colorado, Florida, Illinois, Indiana, Missouri, New Jersey, New York
2023-11-07
Recruiting
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658Cancer
MBrace Therapeutics
Phase 1/2
130
California, Colorado, Georgia, Illinois, Indiana, Michigan, Nevada, New Jersey
2023-11-07
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu-177 vipivotide tetraxetan·Pasritamig
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
DrugsKB707·Opdualag·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
240
California, Florida, Indiana, Michigan, Nebraska, New Jersey, New York, Ohio
2023-10-31
Active, closed
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
NCT05657301Age-Related Macular Degeneration
DrugKH631
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
25
Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas
2023-10-16
Active, closed
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
DrugsZimberelimab·Fluorouracil·Leucovorin·Oxaliplatin
Arcus Biosciences, Inc.
Phase 1
40
Arizona, Florida, Illinois, Michigan, Minnesota, New Jersey, Ohio, Texas
2023-10-13
Active, closed
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689Myelodysplastic Syndromes
DrugsReblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Recruiting
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131Peripheral T Cell Lymphoma
DrugsBelinostat·Pralatrexate·CHOP·Prednisone
Acrotech Biopharma Inc.
Phase 3
504
California, Colorado, Florida, Kentucky, Michigan, New Jersey, Texas
2023-10-04
Active, closed
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649Hearing Loss, Conductive, Hearing Loss, Mixed
Med-El Corporation
Not applicable
36
Colorado, Florida, New Jersey, North Carolina, Ohio, Utah
2023-10-03
Active, closed
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584Geographic Atrophy
DrugsSyfovre·Pegcetacoplan
Apellis Pharmaceuticals, Inc.
Observational
300
California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, New Jersey
2023-09-28
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
DrugTividenofusp alfa
Denali Therapeutics Inc.
Phase 2/3
99
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2023-09-20
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey
2023-09-08
Active, closed
Venclose digiRF System Post Market Study
NCT05504070Venous Reflux, Chronic Venous Insufficiency
C. R. Bard
Not applicable
203
Colorado, Hawaii, Michigan, New Jersey, North Carolina, Texas, Virginia
2023-09-08
Active, closed
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT05979779Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
DrugHU6
Rivus Pharmaceuticals, Inc.
Phase 2
219
California, Florida, Louisiana, New Jersey, North Dakota, Texas
2023-09-05
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Alabama, California, Florida, Georgia, Indiana, Kentucky, New Jersey, New York
2023-08-31
Recruiting
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706Advanced or Metastatic Solid Tumor
DrugPembrolizumab
Pliant Therapeutics, Inc.
Phase 1
124
Connecticut, Georgia, Michigan, Missouri, New Jersey, New York, North Carolina, South Dakota
2023-08-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954Malignant Neoplasm of Breast
Novian Health Inc.
Not applicable
122
California, Connecticut, Maryland, New Jersey, New York
2023-08-09
Active, closed
The BD Liverty™ TIPS Stent Graft Study
NCT05711316Portal Hypertension, TIPS
C. R. Bard
Not applicable
177
California, District of Columbia, Indiana, Kansas, Massachusetts, Missouri, New Jersey, New York
2023-08-08
Active, closed
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553SCN2A Encephalopathy, SCN8A Encephalopathy
DrugRelutrigine
Praxis Precision Medicines
Phase 2/3
77
Georgia, Illinois, Minnesota, New Jersey
2023-08-02
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee
2023-07-31
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
DrugsINCA33890·ADG126·Folfiri·Folfox
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
DrugsFutibatinib·Leucovorin·Irinotecan·Adrucil
Taiho Oncology, Inc.
Phase 2
53
California, Colorado, Florida, Michigan, New Jersey, New York, Ohio, Pennsylvania
2023-07-13
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
By invitation
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
NCT05143307HIV-1-infection
Excision BioTherapeutics
Phase 1
9
California, Missouri, New Jersey
2023-07-11
Active, closed
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
95
Illinois, Kentucky, New Jersey
2023-07-06
By invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
NCT05872022Pregnancy, Obesity, Overweight
Novo Nordisk A/S
Observational
728
New Jersey
2023-07-05
Active, closed
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05601752Ovarian Cancer
USWM CT, LLC
Phase 2
66
Arizona, California, Georgia, Michigan, New Jersey, Ohio, Oklahoma, South Dakota
2023-06-26
Active, closed
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
NCT05520099Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
Elephas
Observational
416
Arkansas, California, Florida, Kentucky, Maryland, New Jersey, New York, North Carolina
2023-06-26
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
DrugEnvudeucitinib
Alumis Inc
Phase 2
408
Alabama, California, Florida, Georgia, Missouri, Nevada, New Jersey, New Mexico
2023-06-26
Active, closed
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
DrugVOY-101
Perceive Biotherapeutics, Inc.
Phase 1/2
60
Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas
2023-06-21
Recruiting
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
NCT05758545Diabetic Foot Ulcer
Piomic Medical
Not applicable
450
Arizona, California, Florida, Georgia, Illinois, New Jersey, New York, North Carolina
2023-06-19
Recruiting
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
NCT05915078Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Smith & Nephew, Inc.
Observational
200
Kentucky, New Jersey, New York, Utah
2023-06-15
Recruiting
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535Cachexia
AVEO Pharmaceuticals, Inc.
Phase 1
30
California, Connecticut, Florida, Nebraska, New Jersey, New York, Oregon, South Carolina
2023-06-13
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
DrugVenetoclax
AbbVie
Phase 1
135
Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio
2023-06-09
Rows per page Showing 1–500 of 782
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-jersey

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 782 of those studies with a site in New Jersey.

How many clinical trials are recruiting in New Jersey?

416 of the 782 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 25 have not yet opened recruitment, 317 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New Jersey), 782 studies
PhaseStudiesRecruitingShare
Phase 21557219.8%
Phase 31507019.2%
Phase 11399017.8%
Phase 1/21117314.2%
Observational1005912.8%
Not applicable943712%
Phase 2/321112.7%
Phase 41041.3%
Phase EARLY_PHASE1200.3%

Most active sponsors

Lead sponsors with the most studies (New Jersey)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3424
AstraZeneca3113
Novartis Pharmaceuticals2417
Bristol-Myers Squibb2214
Pfizer219
Janssen Research & Development, LLC176
AbbVie158
Hoffmann-La Roche156
Regeneron Pharmaceuticals127
Daiichi Sankyo116
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.